Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Covington
Novartis
Cerilliant
US Army
Fish and Richardson
Farmers Insurance
Merck
Accenture
Cantor Fitzgerald

Generated: October 22, 2017

DrugPatentWatch Database Preview

Desipramine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for desipramine hydrochloride and what is the scope of desipramine hydrochloride patent protection?

Desipramine hydrochloride
is the generic ingredient in three branded drugs marketed by Sandoz, Actavis Totowa, Ani Pharms Inc, Amneal Pharms Co, Sanofi Aventis Us, Heritage Pharms Inc, Impax Labs Inc, Usl Pharma, and Us Pharm Holdings, and is included in twenty-one NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for desipramine hydrochloride. Sixteen suppliers are listed for this compound.

Summary for Generic Name: desipramine hydrochloride

US Patents:0
Tradenames:3
Applicants:9
NDAs:21
Drug Master File Entries: see list9
Suppliers / Packagers: see list16
Bulk Api Vendors: see list37
Clinical Trials: see list2,340
Patent Applications: see list1,630
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:desipramine hydrochloride at DailyMed

Pharmacology for Ingredient: desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL205153-004Oct 28, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Impax Labs Inc
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL205153-001Oct 28, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL072103-001Jun 20, 1988ABRXNoNo► Subscribe► Subscribe► Subscribe
Actavis Totowa
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL071766-001Oct 5, 1987ABRXNoNo► Subscribe► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Sandoz
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL072102-001Jun 20, 1988ABRXNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Usl Pharma
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL071866-001Sep 9, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL071803-005May 29, 1997RXNoNo► Subscribe► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-006Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-007Feb 11, 1982► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-006Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-006Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
NORPRAMIN
desipramine hydrochloride
TABLET;ORAL014399-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Healthtrust
AstraZeneca
Accenture
Boehringer Ingelheim
Johnson and Johnson
Fuji
Colorcon
Fish and Richardson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot